Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib-Pembrolizumab Maintenance Therapy in Advanced Unresectable Pancreatic Cancer
NCT04887805Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jul 2021
- Primary completion
- Mar 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, pembrolizumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by City of Hope. Started Jul 2021; status: active, not recruiting.
02
Drugs
lenvatinibpembrolizumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04887805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04887805.